Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved entities : Bausch health companies inc. save search
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Published: 2023-05-17 (Crawled : 22:00) - biospace.com/
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 1.0%
H: 40.79%
C: 22.86%
fda drug approval application
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
Published: 2022-09-09 (Crawled : 21:00) - biospace.com/
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 0.15%
H: 14.61%
C: 10.28%
fda tentative health approval
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
Published: 2022-03-24 (Crawled : 12:00) - biospace.com/
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -1.68%
relistor therapy injection
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries
Published: 2022-02-23 (Crawled : 07:00) - globenewswire.com
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: -3.39%
H: 4.3%
C: 0.44%
commercialization
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
Published: 2021-12-06 (Crawled : 13:00) - biospace.com/
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
approval granted grant
Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
Published: 2021-11-16 (Crawled : 12:30) - globenewswire.com
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 0.52%
H: 0.26%
C: -1.04%
RGNX | $17.84 -1.0% 73K
|
Health Technology
|
| O: -17.59%
H: 2.67%
C: 1.05%
CLSD | $1.2 -6.98% 290K
|
Health Technology
|
| O: -2.56%
H: 0.0%
C: 0.0%
presentation fda xipere fda approval
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published: 2021-10-25 (Crawled : 11:00) - biospace.com/
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 0.28%
H: 1.95%
C: 0.9%
CLSD | $1.2 -6.98% 290K
|
Health Technology
|
| O: 3.49%
H: 8.51%
C: -0.89%
treatment fda ema fda approval approval macular xipere injection
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 0.44%
H: 1.19%
C: 0.2%
license approval
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
Published: 2021-05-04 (Crawled : 06:00) - globenewswire.com
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: -4.84%
H: 0.54%
C: -6.56%
license approval
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL
Published: 2021-04-16 (Crawled : 06:00) - globenewswire.com
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 0.3%
H: 0.36%
C: -1.18%
brazil approval health
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
Published: 2021-04-07 (Crawled : 12:00) - prnewswire.com
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: -0.1%
H: 1.33%
C: 1.09%
fda device approval fda approval
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.